![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/09\/4000-vitality-new.png\")
<\/p>\n<\/p>\n
Vitality Biopharma, Inc.<\/strong>, a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan<\/strong> & Co.<\/strong>, an internationally recognized investment banking firm, to advise Vitality on its strategic alternatives, including potential financings, asset divestitures or strategic partnerships.<\/p>\n “We are thrilled to be working with DelMorgan to evaluate strategic alternatives for our Company”, stated Vitality’s CEO, Michael Cavanaugh. “Vitality has a unique and differentiated portfolio of glycosylated cannabinoid prodrugs advanced to a key development stage and DelMorgan’s deep capital markets expertise and well-earned trust within the investment community provides our organization with the perfect partner to guide us through the process of evaluating strategic alternatives to maximize value for all of our shareholders.”<\/p>\n Rob Delgado, Chairman of DelMorgan & Co., continued, “We are excited by Vitality’s novel prodrugs, which have the potential to introduce promising new treatments for Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) by neutralizing the unwanted side effects of cannabinoids, including the psychoactive effects of THC.” Neil Morganbesser, President & CEO of DelMorgan & Co., added, “Vitality is at a natural inflection point, with lots of promising growth opportunities to turn its innovative glycosylation technology into a broad portfolio of prodrugs. The right partner – either through M&A or a capital infusion – could be the key to unlocking Vitality’s explosive growth potential.”<\/p>\n About Vitality Biopharma, Inc.<\/strong><\/p>\n Headquartered in Los Angeles, California, Vitality Biopharma Inc. (www.vitality.bio) is a company focused on the advancement of pharmaceuticals and innovative technologies that improve the lives of patients. Vitality seeks to achieve this objective through the development of novel glycosylated cannabinoid prodrugs that are engineered to deliver the therapeutic benefits of cannabinoids but without their unwanted side effects. Vitality has developed over 100 novel cannabinoid compounds, including glycosylated tetrahydrocannabinol (THC) and water soluble glycosylated cannabidiol (CBD) prodrugs.<\/p>\n About <\/strong>DelMorgan<\/strong> & Co.<\/strong><\/p>\n Headquartered in Santa Monica, California, DelMorgan & Co. (www.delmorganco.com) is an internationally recognized investment bank and financial advisor. With over three decades of experience and over $300 billion in successfully completed transactions, the professionals at DelMorgan & Co. provide world-class financial advice and assistance to companies, institutions, governments and individuals around the world.<\/p>\n Vitality Biopharma, Inc.<\/strong> DelMorgan<\/strong> & Co.<\/strong> Tags:<\/b> Investor Relations
Investor Relations
info@vitality.bio
+1 530.231.7800
www.vitality.bio<\/p>\n
Rob Delgado, Chairman or Neil Morganbesser, President & CEO
inquiries@delmorganco.com
+1 310.319.2000
www.delmorganco.com<\/p>\nSee Campaign: <\/strong>http:\/\/www.vitality.bio<\/a>
Contact Information:<\/b>
Investor Relations
\ninfo@vitality.bio
\n+1 530.231.7800
\nwww.vitality.bio<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\ninfo@vitality.bio
\n+1 530.231.7800
\nwww.vitality.bio<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":" Vitality Biopharma, Inc., a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan & Co., an internationally recognized investment banking firm, to advise Vitality on its strategic alternatives, including potential financings, asset divestitures or strategic partnerships. “We are thrilled to be working with DelMorgan to evaluate strategic … Continue reading Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives<\/span><\/a> Continue Reading